GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC).
• Mechanisms of AR signaling in CRPC are not fully understood.
• Identifying novel AR coregulators is crucial for understanding CRPC progression.

Purpose of the Study:

• To identify novel AR coregulators in CRPC.
• To elucidate the dual role of GNL3 in AR transcriptional programs.
• To investigate GNL3 as a potential therapeutic target in advanced prostate cancer.

Main Methods:

• Proteomic profiling of CRPC and primary prostate cancer cells.
• Assessment of GNL3 interaction with AR and its effect on chromatin occupancy.
• Analysis of GNL3's impact on cell proliferation and immune gene expression.
• Evaluation of GNL3 knockdown effects on CRPC cell sensitivity to AR antagonists and tumor progression.

Main Results:

• G Protein Nucleolar 3 (GNL3) was identified as a novel AR coregulator.
• GNL3 enhances AR-mediated transcription of proliferation genes (e.g., NEK2, CDC20).
• GNL3 represses immune-responsive genes (e.g., CXCL10, TAP1) via HDACs, promoting immune evasion.
• Increased GNL3 expression correlates with poor clinical outcomes in prostate cancer.
• GNL3 knockdown sensitizes CRPC cells to AR antagonists and reduces tumor growth/metastasis.

Conclusions:

• GNL3 acts as a dual-function AR coregulator, promoting proliferation and immune suppression in CRPC.
• GNL3 is a promising therapeutic target for advanced prostate cancer.
• Combinatorial inhibition of NEK2, HDACs, and AR signaling may represent a viable therapeutic strategy for CRPC.